no Obvious AbnormalitiesNCT07291960
Retinal Clinical Assessment With AI-derived Quantitative Information
An observational study of no Obvious Abnormalities and Diabetic Retinopathy (DR), run by Beijing Tongren Hospital.
Trial summary
This randomized controlled trial evaluates whether providing clinicians with AI-derived quantitative retinal information improves the quality and efficiency of retinal clinical assessment. Participating ophthalmologists and ophthalmology trainees will be randomly assigned to one of two groups. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- no Obvious Abnormalities, Diabetic Retinopathy (DR), AMD
- What is being tested?
- AI-derived retinal quantitative information-assisted reporting
- How many people
- 29 participants
- Where
- No sites listed yet
- Study dates
- 15 Apr 2026to 15 May 2026
- How long will I take part?
- 21 Days
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: The study population consists of practicing ophthalmologists and ophthalmology trainees who are responsible for interpreting fundus images and generating clinical reports. These clinicians will be randomly assigned to either the intervention group, which has access to AI-derived quantitative retinal information during report writing, or the control group, which performs report writing using only the original fundus images without AI assistance. A separate panel of senior ophthalmologists, who are not involved in the reporting task, will serve as blinded expert evaluators. They will independently assess all completed reports based on predefined quality dimensions, including accuracy, completeness, clarity, and consistency of interpretation. The retinal fundus images used in this study are de-identified clinical images representing a range of normal and abnormal retinal presentations. All images are of sufficient quality for interpretation and contain no patient-identifiable information
Who may be able to join
- Clinician Participants (Report Writers)
- Board-certified ophthalmologists or ophthalmology trainees (registrars or fellows) with clinical experience in interpreting fundus images.
- Capable of independently completing retinal clinical reports based on fundus photography.
- Willing and able to participate in the study tasks (report writing) under assigned study conditions.
- Able to provide informed consent.
- Expert Evaluators (Outcome Assessors)
Show all 14Show fewer
- Senior ophthalmologists with at least 5 years of post-certification clinical experience.
- Not involved in the report-writing stage of the study.
- Willing to evaluate de-identified reports across predefined quality dimensions.
- Able to provide informed consent.
- Fundus Images (Data Inputs)
- Retinal fundus photographs of sufficient quality for clinical interpretation.
- Images representing a range of common retinal findings (normal or abnormal).
- Previously collected, de-identified images with no patient-identifiable information.
Who cannot join
- Clinician Participants
- Lack of experience in interpreting fundus images (e.g., interns, medical students).
- Prior involvement in the development, training, or validation of the AI system being tested.
- Inability to complete reporting tasks due to time constraints or technical limitations.
- Any condition that may interfere with ability to perform study tasks (e.g., prolonged absence).
- Expert Evaluators
Show all 13Show fewer
- Participation in the intervention or control reporting arms.
- Prior exposure to or involvement in development of the AI system.
- Any conflict of interest affecting impartiality of report quality evaluation.
- Fundus Images
- Poor-quality images with insufficient clarity for interpretation.
- Images containing artifacts or cropping that prevent accurate segmentation or assessment.
- Images with any remaining patient identifiers (excluded to maintain confidentiality).
About this study
Official title: AI-derived Retinal Quantification Versus Routine Clinical Interpretation in Ophthalmic Assessment: a Randomized Controlled Trial
This randomized controlled trial evaluates whether providing clinicians with AI-derived quantitative retinal information improves the quality and efficiency of retinal clinical assessment. Participating ophthalmologists and ophthalmology trainees will be randomly assigned to one of two groups. The intervention group will write clinical reports with access to automated quantitative measurements generated from fundus image analysis, including multiple retinal structural and vascular biomarkers. The control group will complete the same reporting tasks using only the original fundus images without AI-generated quantitative information.
All reports produced by both groups will be de-identified and independently evaluated by a separate panel of senior ophthalmologists who are blinded to group allocation. The expert evaluators will assess report accuracy, completeness, clarity, and overall clinical quality using predefined scoring criteria. The study aims to determine whether access to quantitative retinal biomarkers enhances clinicians' reporting performance and reduces reporting time during retinal assessment tasks.
- Conditions
- no Obvious Abnormalities, Diabetic Retinopathy (DR), AMD, Cup-to-disc Ratio Bigger Than 0.5, Pathological Myopia, Macular Hole
- Being tested
- AI-derived retinal quantitative information-assisted reporting
- Medical subject headings
- Diabetic Retinopathy, Myopia, Degenerative, Retinal Perforations, Epiretinal Membrane, Retinal Vein Occlusion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-derived retinal quantitative information-assisted reportingDiagnostic test
Clinicians assigned to the intervention arm will complete retinal clinical reports with access to an AI system that provides automated retinal feature quantification. The system generates multiple quantitative retinal biomarkers-including vessel characteristics, optic nerve head metrics, macular indices, and other region-specific structural measurements-derived from automated segmentation of each fundus image.
During report writing, clinicians can view these AI-generated quantitative values alongside the image. The system does not provide diagnostic labels, impressions, or textual interpretations; it only supplies numerical measurements intended to support clinicians' assessment. All clinical judgments, narrative descriptions, and final conclusions in the report are made solely by the clinician.
| Study group | Role | What they receive |
|---|---|---|
| AI-derived retinal quantification | Not described Receives: Diagnostic Test: AI-derived retinal quantitative information-assisted reporting | |
| Routine clinical interpretation | Not described | |
| Outcome Assessor | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Expert-rated clinical report quality
All clinical reports generated by clinicians in both the AI-assisted and control groups will be anonymized and independently evaluated by a separate panel of senior ophthalmologists who are blinded to group allocation. The expert evaluators will score each report using predefined criteria assessing accuracy, completeness, clarity, consistency with the fundus image, and overall clinical quality. Scores will be recorded using a standardized multi-dimensional rating scale. The primary outcome is the mean overall quality score per report.
Measured: Assessed after completion of all reporting tasks (approximately 1-2 weeks per participant)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2025
- Study start15 Apr 2026 (estimated)
- Primary completion15 May 2026 (estimated)
- Study completion15 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for no Obvious AbnormalitiesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 29 participants (estimated)
- Target duration
- 21 Days
Sponsor and investigators
- Lead sponsor
- Beijing Tongren Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07291960
- Sponsor's protocol ID
- TRECK2018-056-GZ(2022)-07
- Status last verified
- Dec 2025
- First submitted
- 5 Dec 2025
- Last updated
- 29 Apr 2026
- Results posted
- No